Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
Abstract Background An over-expression of the epidermal growth factor receptor (EGFR) has been observed in colorectal cancer and is associated with aggressive disease and poor prognosis. SCT200 is a newly developed recombinant, fully humanized, anti-EGFR monoclonal antibody. This study aimed to eval...
Main Authors: | Wen Zhang, Xiaohong Han, Lin Yang, Yuanyuan Song, Liangzhi Xie, Wenlin Gai, Yan Wang, Yuankai Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-022-10147-9 |
Similar Items
-
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
by: Ming Bai, et al.
Published: (2022-03-01) -
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ studyResearch in context
by: Lin Yang, et al.
Published: (2024-02-01) -
Development of Learning Model Tools STEAM-based SCT in Wetland Environment Theme
by: Norsalehah Norsalehah, et al.
Published: (2022-06-01) -
Factors Affecting Users’ Continuous Usage in Online Health Communities: An Integrated Framework of SCT and TPB
by: Zhuolin Cao, et al.
Published: (2023-04-01) -
“sCT-Feasibility” - a feasibility study for deep learning-based MRI-only brain radiotherapy
by: Johanna Grigo, et al.
Published: (2024-03-01)